NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments ...

Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Lila Sciences' already impressive $235 million first round financing has continued to build and has now closed at $350 ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, ...

IOI Properties Group, the Malaysia-listed property giant, will open its public launch of the 683-unit W Residences Marina ...

Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) Provides non-dilutive capital and additional financial ...

AbbVie today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the ...

Although teplizumab doesn’t work for everyone and how much it delays progression varies, it has inspired new directions in ...